Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast
He predicted the 2020 crash a month before it happened…He predicted this year’s collapse back in January…

And now, he’s issuing a brand-new warning – along with a unique solution.
Details here.
Steve Aselage net worth and biography

Steve Aselage Biography and Net Worth

Mr. Aselage has been a member of the board of directors of Travere Therapeutics, Inc. since 2012. During his tenure as CEO of Travere from 2014 to January 2019, Mr. Aselage drew upon more than 30 years of biopharmaceutical experience to lead the transformation of the company. Following his appointment, Mr. Aselage solidified the company’s leadership, led an operational review of pipeline and commercial assets, and built a growth strategy around investigational and commercial therapies to bring long-term value to patients and shareholders. Prior to his appointment, Mr. Aselage was executive vice president and chief business officer of BioMarin Pharmaceutical Inc. During his seven years with BioMarin, Mr. Aselage built the commercial and medical affairs functions that launched three commercial products and developed commercial businesses in more than 45 countries. Mr. Aselage has also held leadership roles with Cell Therapeutics, Sangstat Medical Corporation, Advanced Tissue Sciences and Genentech. Mr. Aselage worked briefly for Genzyme, as well, assisting in the transition following its acquisition of Sangstat, and earlier in his career, held a variety of sales and sales management positions at companies including Rhone-Poulenc Rorer Pharmaceuticals (now Sanofi) and Bristol Laboratories. Mr. Aselage is also a member of the board of directors for Acer Therapeutics and BioCryst. Mr. Aselage received his B.S. in biology from the University of Notre Dame, and currently serves on the advisory council for the Department of Science at Notre Dame.

What is Steve Aselage's net worth?

The estimated net worth of Steve Aselage is at least $3.64 million as of May 11th, 2022. Mr. Aselage owns 146,919 shares of Travere Therapeutics stock worth more than $3,639,184 as of September 26th. This net worth estimate does not reflect any other assets that Mr. Aselage may own. Learn More about Steve Aselage's net worth.

How do I contact Steve Aselage?

The corporate mailing address for Mr. Aselage and other Travere Therapeutics executives is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. Travere Therapeutics can also be reached via phone at (888) 969-7879 and via email at [email protected] Learn More on Steve Aselage's contact information.

Has Steve Aselage been buying or selling shares of Travere Therapeutics?

Steve Aselage has not been actively trading shares of Travere Therapeutics within the last three months. Most recently, Steve Aselage sold 2,575 shares of the business's stock in a transaction on Wednesday, May 11th. The shares were sold at an average price of $21.92, for a transaction totalling $56,444.00. Following the completion of the sale, the director now directly owns 146,919 shares of the company's stock, valued at $3,220,464.48. Learn More on Steve Aselage's trading history.

Who are Travere Therapeutics' active insiders?

Travere Therapeutics' insider roster includes Steve Aselage (Director), Sandra Calvin (CAO), Laura Clague (CFO), Eric Dube (CEO), Peter Heerma (Insider), Elizabeth Reed (SVP), Noah Rosenberg (Insider), and William Rote (SVP). Learn More on Travere Therapeutics' active insiders.

Are insiders buying or selling shares of Travere Therapeutics?

During the last year, insiders at the sold shares 20 times. They sold a total of 146,949 shares worth more than $3,961,476.48. The most recent insider tranaction occured on September, 13th when CAO Sandra Calvin sold 349 shares worth more than $9,772.00. Insiders at Travere Therapeutics own 4.7 % of the company. Learn More about insider trades at Travere Therapeutics.

Information on this page was last updated on 9/13/2022.

Steve Aselage Insider Trading History at Travere Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/11/2022Sell2,575$21.92$56,444.00146,919View SEC Filing Icon  
11/16/2021Sell31,800$29.39$934,602.00View SEC Filing Icon  
11/5/2021Sell10,000$26.23$262,300.00View SEC Filing Icon  
10/7/2021Sell60,000$26.25$1,575,000.00View SEC Filing Icon  
4/16/2021Sell10,000$26.23$262,300.00198,940View SEC Filing Icon  
3/17/2021Sell17,727$27.44$486,428.88206,667View SEC Filing Icon  
See Full Table

Steve Aselage Buying and Selling Activity at Travere Therapeutics

This chart shows Steve Aselage's buying and selling at Travere Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Travere Therapeutics Company Overview

Travere Therapeutics logo
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $24.77
Low: $24.07
High: $24.85

50 Day Range

MA: $26.20
Low: $22.91
High: $28.63

2 Week Range

Now: $24.77
Low: $20.80
High: $31.65


658,800 shs

Average Volume

726,815 shs

Market Capitalization

$1.57 billion

P/E Ratio


Dividend Yield